Survey of Clinical Protocols for the Use of 177 Lu-PSMA-617 in the United States.
| Autor: | Kuo PH; Department of Medical Imaging, University of Arizona, Tucson, Arizona; pkuo@email.arizona.edu., Covington MF; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah.; Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, Utah., Lee DJ; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas., Wong TZ; Departments of Radiology (Nuclear Medicine and Radiotheranostics) and Medicine (Medical Oncology), Duke Health, Durham, North Carolina., Pandit-Taskar N; Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.; Department of Radiology, Weil Cornell Medical Center, New York, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of nuclear medicine technology [J Nucl Med Technol] 2024 Sep 05; Vol. 52 (3), pp. 208-211. Date of Electronic Publication: 2024 Sep 05. |
| DOI: | 10.2967/jnmt.123.266769 |
| Abstrakt: | Although guidelines for the use of 177 Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a brief survey was performed to assess key components of the 177 Lu-PSMA-617 protocol before, during, and after delivery of therapy. This survey demonstrated the wide variability in many aspects of institutional protocols regarding determination of eligibility for and administration of 177 Lu-PSMA-617 therapy. The real-world protocol details provided here from a variety of institutions may help new and established theranostic programs. (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|